AURELIA ONLINEMounjaro 12.5 mg and 15 mg: Maximum Dose, Escalation, Effects and Side Effects
This English page provides medical information and booking guidance. Consultation may be conducted in Japanese or English. Tell the doctor the country where you are physically located. Medication supplied through this service is received in Japan by the patient; proxy pickup and direct overseas delivery are not supported.
Mounjaro 12.5 mg and 15 mg are the two highest strengths in the Japanese dose range. They are not starting doses. They are considered only after stepwise titration and a review of benefit, adverse effects, nutrition, weight trajectory and—when treating type 2 diabetes—glycemic control.
- 15 mg once weekly is the maximum dose in the Japanese Mounjaro label.
- Dose increases are made in 2.5 mg steps after at least 4 weeks at the current dose when the response is insufficient and tolerability is acceptable.
- 12.5 mg is a marketed strength, but major obesity trials generally used 10 mg and 15 mg as fixed target groups; do not invent a “12.5 mg average weight-loss rate” by interpolation.
- Higher dose does not mean every patient needs the maximum dose.
- Persistent gastrointestinal symptoms, very low intake or excessive weight loss are reasons to reassess the dose.
How 12.5 mg and 15 mg fit into titration
| Step | Typical role |
|---|---|
| 10 mg | Higher maintenance dose when lower doses are insufficient |
| 12.5 mg | Next 2.5 mg step if 10 mg is insufficient and tolerated |
| 15 mg | Maximum once-weekly dose |
What did trials show at 15 mg?
In SURMOUNT-1, adults with obesity or overweight without diabetes assigned to the 15 mg target group had a mean weight change of −20.9% at 72 weeks, compared with −19.5% for 10 mg and −15.0% for 5 mg. These are trial averages, not an individual prediction.
In SURPASS-2, adults with type 2 diabetes assigned to 15 mg had a mean body-weight change of about −11.2 kg at 40 weeks. Trial populations, titration schedules and treatment goals differ, so numbers should not be transferred directly to an individual.
Why not rush from 12.5 mg to 15 mg?
If weight or glucose is still improving at 12.5 mg, or if nausea, constipation, vomiting or reduced intake remains significant, there may be no advantage in rushing to 15 mg. The clinical question is not “Can I reach the maximum?” but “Is additional dose likely to provide more benefit than burden?”
Side effects that matter more at high doses
Nausea, diarrhea, constipation, vomiting, abdominal discomfort, dyspepsia and reduced appetite.
Persistent severe abdominal pain, repeated vomiting with dehydration, marked abdominal distension/constipation, jaundice or allergic symptoms.
15 mg does not mean “the strongest is always best”
Some patients obtain adequate benefit at 10 mg or 12.5 mg. Staying at a lower effective dose may be reasonable when treatment goals are met. Conversely, 15 mg may be considered after an adequate 12.5 mg period when effect remains insufficient and tolerability is acceptable.
Long-term treatment after reaching a high dose
After substantial weight loss, the goal often changes from further loss to maintenance. A later dose reduction may be considered when side effects, excessive weight loss or maintenance goals make a lower dose more appropriate. Long-term treatment is discussed in our high-dose maintenance guide.
Before requesting 12.5 mg or 15 mg
- Current and previous dose
- How many weeks you have used each dose
- Date of your last injection
- Starting and current weight
- Side effects and bowel symptoms
- Other diabetes medications
- Any upcoming surgery or deep sedation
Frequently asked questions
Is 15 mg the maximum Mounjaro dose in Japan?
Yes. The Japanese Mounjaro label lists 15 mg once weekly as the maximum dose.
Do I have to reach 15 mg?
No. If a lower dose provides sufficient benefit and is well tolerated, there may be no need to escalate.
Is 12.5 mg just a temporary step?
Not necessarily. It is a marketed strength and may be continued when clinically appropriate, although large fixed-dose obesity trials provide less direct 12.5 mg-specific outcome data.
Can I go directly from 10 mg to 15 mg?
Standard titration uses 2.5 mg steps with at least 4 weeks between increases, so skipping 12.5 mg is not the labeled escalation approach.
References
- PMDA. Mounjaro Japanese package insert, revision September 2026.
- Jastreboff AM, et al. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). N Engl J Med. 2022.
In Japan, Mounjaro is approved for type 2 diabetes. Use of Mounjaro for weight management is off-label. Obesity-trial data are cited as medical evidence about tirzepatide, not as a statement that Mounjaro is approved for obesity in Japan.